Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer

Tolerability and toxicity of olaparib capsules is similar between women ≥ 65 years and < 65 years of age treated for advanced recurrent ovarian cancer. Use of olaparib should be considered in this patient population.